Nanobiotix S.A. ADR (NBTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBTX Stock Price Chart Interactive Chart >
NBTX Price/Volume Stats
|Current price||$5.76||52-week high||$18.00|
|Prev. close||$5.82||52-week low||$4.65|
|Day high||$5.76||Avg. volume||5,259|
|50-day MA||$6.53||Dividend yield||N/A|
|200-day MA||$9.95||Market Cap||200.60M|
Nanobiotix S.A. ADR (NBTX) Company Bio
Nanobiotix SA engages in the development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Most Popular Stories View All
NBTX Latest News Stream
|Loading, please wait...|
NBTX Latest Social Stream
View Full NBTX Social Stream
Latest NBTX News From Around the Web
Below are the latest news stories about Nanobiotix SA that investors may wish to consider to help them evaluate NBTX as an investment opportunity.
PARIS, February 10, 2022--Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
View more earnings on DYAISee more from BenzingaEnsign Group Shares Gain On Mixed Q4 Results, Better-Than-Expected FY22 OutlookNanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Nanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient
Nanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology. The case study reports on the first patient treatment experience with potential first-in-class radioenhancer NBTXR3 in pancreatic ductal adenocarcinoma. Nanobiotix and MD Anderson are collaborating to expand the development of NBTXR3 beyond the Company's priority pathways in locally advanced head and neck squamous cell carcinoma and immunotherapy. This ongoing P
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
PARIS & CAMBRIDGE, Mass., February 09, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of a peer-reviewed case study by researchers at The University of Texas MD Anderson Cancer Center in Clinical and Translational Radiation Oncology. The case study reports on the first patient experience o
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
PARIS & CAMBRIDGE, Mass., January 26, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the publication of new preclinical immunotherapy data for novel, potentially solid tumor- and therapeutic combination-agnostic radioenhancer NBTXR3 in the Journal of Nanobiotechnology.
NBTX Price Returns